A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Clinical Trial

Official title:

A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-cell Non-Hodgkin Lymphoma (NHL)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03299738
• Other study ID #: CBMG-C2017006
• Status: Not yet recruiting
• Phase: Phase 1
• First received: September 28, 2017
• Last updated: December 18, 2017
• Start date: December 2017
• Est. completion date: August 2019

Study information

• Verified date: December 2017
• Source: Cellular Biomedicine Group Ltd.
• Contact: Huilai Zhang
• Phone: +86-022-23340123
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).

Description:

The study will include the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), Treatment and Follow-up.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: August 2019
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Volunteered to participate in this study and signed informed consent

2. Age 18-70 years old, male or female

3. Relapse or refractory B cell non-Hodgkin's lymphoma

• 1. Histologically diagnosed as DLBCL (including PMBCL) or follicular lymphoma (grade ?b) according to the NCCN non-Hodgkin's lymphoma Clinical Practice Guidelines (2017 Version 1)

• Progressive disease after the last standard chemotherapy regimens per the IWG Response Criteria (1999)

• Stable disease after the last standard chemotherapy regimens (at least 4 cycles of first-line therapy or 2 cycles of later-line therapy) per the IWG Response Criteria (1999)

• Relapse or progressive disease within 12 months after autologous stem cell transplantation (SCT)

• 2. Follicular lymphoma (stage ?-?) (grade?-?a)

• At least 2 combination chemotherapy regimens (excluding single agent monoclonal antibody)

• Relapse or progressive disease within 1 year after last chemotherapy regimens

• 3. Mantle cell lymphoma

• Relapse after 1st CR or persistent disease, and not eligible or appropriate for SCT

• Relapse or progressive disease within 1 year after the last chemotherapy regimens

• Relapse or progressive disease within 12 months after autologous SCT

4. All subjects must have received anti-CD20 monoclonal antibody (unless tumor is CD20-negative) and anthracycline-containing chemotherapy regimens according to NCCN non-Hodgkin lymphoma Clinical Practice Guidelines (2017 Version 1)

5. At least one measurable lesion per revised IWG Response Criteria (the longest diameter of the tumor = 1.5 cm)

6. Expected survival = 12 weeks

7. ECOG score 0-1

8. Left ventricular ejection fraction (LVEF) = 50% (detected by echocardiography)

9. No active pulmonary infections, normal pulmonary function and oxygen saturation = 92% on room air

10. At least 2 weeks from receiving previous treatment (radiotherapy or chemotherapy) prior to leukapheresis, or at least 4 weeks from monoclonal antibody therapy prior to CAR T cell therapy

11. No contraindications of leukapheresis

12. Female subjects in childbearing age, their serum or urine pregnancy test must be negative, and must agree to take effective contraceptive measures during the trial

Exclusion Criteria:

1. History of allergy to cellular products

2. Laboratory tests: absolute neutrophil count < 1.0 × 10^9 /L, platelet count < 50 × 10^9 /L, serum albumin < 30 g/L, serum bilirubin > 1.5 ULN, serum creatinine > ULN, ALT/AST > 3 ULN

3. History of CAR T cell therapy or any other genetically modified T cell therapy

4. Relapse after allogeneic hematopoietic stem cell transplantation

5. Active infections that require treatment (uncomplicated urinary tract infections and bacterial pharyngitis are allowed), prophylactic antibiotic, antiviral and antifungal treatment are permitted

6. Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as acquired or congenital immune deficiency diseases, including but not limited to HIV infection

7. Class III or IV heart failure according to the NYHA Heart Failure Classifications

8. QT interval prolongation = 450 ms

9. History of epilepsy or other central nervous system disorders

10. Evidence of CNS lymphoma by head enhancement scan or magnetic resonance imaging

11. History of other primary cancers, with the following exceptions

• Excisional non-melanoma (e.g. cutaneous basal cell carcinoma)

• Cured in situ carcinoma (e.g. cervical cancer, bladder cancer, breast cancer)

12. Autoimmune diseases that require treatment, immune deficiency diseases or other diseases that require immunosuppressive therapy

13. Used of systemic steroids within two weeks (using inhaled steroids is an exception)

14. Women who are pregnant or lactating, or who have breeding intent in 6 months

15. Participated in any other clinical trial within three months

16. Any situation that investigators believe the risk of the subjects is increased or results of the trial are disturbed

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Non-Hodgkin
• Refractory or Relapsed B-cell Non-Hodgkin Lymphoma

Intervention

Biological:
• C-CAR011
Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg

Locations

Country	Name	City	State
China	Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital	Tianjin

Sponsors (2)

Lead Sponsor	Collaborator
Cellular Biomedicine Group Ltd.	Tianjin Medical University Cancer Institute and Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety: Vital signs, physical examination, clinical laboratory tests, incidence of adverse events (AEs) and serious adverse events (SAEs)	Vital signs, physical examination, clinical laboratory tests, incidence of adverse events (AEs) and serious adverse events (SAEs)	12 weeks
Primary	Overall response rate (ORR)		12 weeks
Secondary	Overall response rate (ORR)		6 months
Secondary	Overall response rate (ORR)		12 months
Secondary	Duration of remission (DOR)		12 months
Secondary	Progression free survival (PFS)		12 months
Secondary	Overall survival (OS)		12 months